Literature DB >> 26126094

Decreasing incidence of renal replacement therapy over time at the critical 50-59-year age range suggests a role for nephroprotective therapy in ADPKD.

Laura Rodriguez-Osorio1, Maria Vanessa Perez-Gomez1, Alberto Ortiz1.   

Abstract

Mesh：

Year:  2015        PMID： 26126094     DOI： 10.1038/ki.2015.95

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


× No keyword cloud information.
  2 in total

1.  Changing referral characteristics of patients with autosomal dominant polycystic kidney disease.

Authors:  Imed Helal; Kim McFann; Berenice Reed; Xiang-Dong Yan; Robert W Schrier
Journal:  Am J Med       Date:  2013-07-03       Impact factor: 4.965

2.  Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease.

Authors:  Edwin M Spithoven; Anneke Kramer; Esther Meijer; Bjarne Orskov; Christoph Wanner; Fergus Caskey; Frederic Collart; Patrik Finne; Damian G Fogarty; Jaap W Groothoff; Andries Hoitsma; Marie-Béatrice Nogier; Maurizio Postorino; Pietro Ravani; Oscar Zurriaga; Kitty J Jager; Ron T Gansevoort
Journal:  Kidney Int       Date:  2014-05-14       Impact factor: 10.612
  2 in total
  3 in total

1.  The Authors Reply.

Authors:  Edwin M Spithoven; Ron T Gansevoort
Journal:  Kidney Int       Date:  2015-07       Impact factor: 10.612

Review 2.  The pathobiology of polycystic kidney disease from a metabolic viewpoint.

Authors:  Luis Fernando Menezes; Gregory G Germino
Journal:  Nat Rev Nephrol       Date:  2019-09-05       Impact factor: 28.314

3.  Meso-American nephropathy: what we have learned about the potential genetic influence on chronic kidney disease development.

Authors:  Maria Vanessa Perez-Gomez; Catalina Martin-Cleary; Beatriz Fernandez-Fernandez; Alberto Ortiz
Journal:  Clin Kidney J       Date:  2018-07-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.